曲妥珠单抗联合帕妥珠单抗新辅助放化疗治疗可切除HER2阳性食管腺癌的II期可行性及生物标志物研究:TRAP研究
该II期研究评估了曲妥珠单抗和帕妥珠单抗联合新辅助放化疗治疗可切除HER2阳性食管腺癌的可行性,主要终点为双靶向药物完成率≥80%。
要点
- 双HER2靶向联合新辅助放化疗可行,83%患者完成双靶向治疗。
- 病理完全缓解率达34%,3年总生存率71%,历史对照显示生存获益。
- HER2 3+过表达和Grb7阳性可能分别预测生存和治疗反应。
核心结论
- 在HER2阳性可切除食管腺癌中,新辅助放化疗联合曲妥珠单抗和帕妥珠单抗是可行的,并相较历史对照显示出潜在 promising 的活性。
- HER2 3+过表达和Grb7阳性可能分别预测生存和治疗反应。
研究设计与样本
- II期可行性研究,入组40例可切除HER2阳性食管腺癌患者(78%男性,中位年龄63岁)。
- 患者接受标准新辅助放化疗(卡铂+紫杉醇,41.4 Gy放疗)联合曲妥珠单抗和帕妥珠单抗。
- 主要终点为可行性,定义为曲妥珠单抗和帕妥珠单抗完成率≥80%。
- 探索性分析包括与倾向性评分匹配队列的生存比较、药代动力学和生物标志物分析。
主要发现
- 33例(83%)患者完成曲妥珠单抗和帕妥珠单抗治疗,未观察到意外安全性事件。
- 所有手术患者均实现R0切除,13例(34%)达到病理完全缓解。
- 中位随访32.1个月,3年无进展生存率和总生存率分别为57%和71%。
- 与倾向性评分匹配队列相比,HER2阻断组总生存显著延长(HR 0.58,95%CI 0.34-0.97)。
关键数值与推荐
- 可行性定义为曲妥珠单抗和帕妥珠单抗完成率≥80%,实际达到83%。
- 3年无进展生存率57%,总生存率71%。
- 与匹配队列比较总生存HR 0.58(95%CI 0.34-0.97)。
临床怎么用
- 对于可切除HER2阳性食管腺癌,可考虑在新辅助放化疗基础上联合曲妥珠单抗和帕妥珠单抗,但需注意该研究为II期可行性研究。
- 治疗前可检测HER2 3+过表达和Grb7状态,以辅助预测生存和治疗反应。
- 药代动力学和FDG PET早期代谢反应不宜作为疗效预测标志物。
局限性
- 本研究为单臂II期可行性研究,样本量较小(40例),结论需进一步验证。
- 与历史对照的比较为探索性倾向性评分匹配分析,存在固有偏倚。
- 生物标志物分析为探索性,预测价值需前瞻性确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy (nCRT) in patients with EAC. PATIENTS AND METHODS: Patients with resectable HER2-positive EAC received standard nCRT with carboplatin and paclitaxel and 41.4 Gy of radiotherapy, with 4 mg/kg of trastuzumab on day 1, 2 mg/kg per week during weeks 2 to 6, and 6 mg/kg per week during weeks 7, 10, and 13 and 840 mg of pertuzumab every 3 weeks. The primary end point was feasibility, defined as ≥ 80% completion of treatment with both trastuzumab and pertuzumab. An exploratory comparison of survival with a propensity score-matched cohort receiving standard nCRT was performed, as were exploratory pharmacokinetic and biomarker analyses. RESULTS: Of the 40 enrolled patients (78% men; median age, 63 years), 33 (83%) completed treatment with trastuzumab and pertuzumab. No unexpected safety events were observed. R0 resection was achieved in all patients undergoing surgery, with pathologic complete response in 13 patients (34%). Three-year progression-free and overall survival (OS) were 57% and 71%, respectively (median follow-up, 32.1 months). Compared with the propensity score-matched cohort, a significantly longer OS was observed with HER2 blockade (hazard ratio, 0.58; 95% CI, 0.34 to 0.97). Results of pharmacokinetic analysis and activity on [18F]fluorodeoxyglucose positron emission tomography scans did not correlate with survival or pathologic response. Patients with HER2 3+ overexpression or growth factor receptor-bound protein 7 (Grb7) -positive tumors at baseline demonstrated significantly better survival (P = .007) or treatment response (P = .016), respectively. CONCLUSION: Addition of trastuzumab and pertuzumab to nCRT in patients with HER2-positive EAC is feasible and demonstrates potentially promising activity compared with historical controls. HER2 3+ overexpression and Grb7 positivity are potentially predictive for survival and treatment response, respectively.
引用
- Stroes CI, Schokker S, Creemers A, et al. Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. J Clin Oncol. 2019. PMID: 31809243. doi:10.1200/JCO.19.01814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。